CYAD News and Press, Celyad SA From 04/30/20

Two accepted abstracts will be presented virtually in a prerecorded poster presentation MONT-SAINT-GUIBERT, Belgium, April 30, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the decision to host its 2020 Ordinary General Meeting...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Celyad SA (CYAD) Q4 2019 Earnings Conference Call March 25, 2020 08:00 a.m. ET Company Representatives Filippo Petti - Chief Executive Officer David Gilham - Vice President of Research & Development Frédéric Lehmann - Vice President of Global Clinical Development an...

First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial  for  patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) CYCLE-1 trial of autologous CYAD-02 for the treatment of r/r AML and MDS ongo...

MONT-SAINT-GUIBERT, Belgium, March 12, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the Company will report full year 2019 financial ...

Introduction Celyad ( CYAD ) is a clinical-stage biopharmaceutical company, focusing on the development of CAR-T cell therapy for treating cancers. The company has both autologous and allogeneic technological platforms for CAR-T and has 2 international partnerships with Novartis and Horizo...

MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the company plans to participate at the following ...

Some people fight fire with fire. I've found water to be more effective. ” - Adrianne Ambrose Today, we go across the pond to take a look at Celyad (CYAD) . This company is a small CAR-T focused ‘ Tier 4 ’ developmental concern that is targeting multiple indication...

Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T c...